We read with interest the paper by Bellomo and colleagues [1] in the previous issue of Critical Care. We agree with the authors' fi nal conclusion that there should not be a deliberate policy to decrease the fraction of inspired oxygen (FiO 2 ) in the absence of accurate and reliable oximetry. In the developed world, accurate and reliable oximetry and blood gas results are ubiquitous in ICU settings, the context of their study. However, we have issues with the methods used to come to the conclusion that hyperoxaemia has only a weak relationship with mortality.
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If one wishes to show no association of hyperoxemia with outcomes, the best approach is to pick the lowest level of arterial partial pressure of oxygen (PaO 2 ). By analogy, if one wished to assess the risk of speeding prior to traffi c accidents, one would not look at the lowest speed or the speed at impact; one would, ideally, look at peak speed or average speed. Kilgannon and colleagues [2] used the fi rst blood gas measurement in the ICU and found that hyperoxemia (PaO 2 of at least 300 mm Hg) was associated with increased risk of death in the hospital. de Jonge and colleagues [3] looked at mean PaO 2 of mechanically ventilated patients in the fi rst 24 hours in ICUs and also reported an increased risk of death in patients with hyperoxemia.
We are also concerned that the conclusion of the study relates to hyperoxemia when defi ned as a PaO 2 of greater than 400 mm Hg whereas the study objective was to analyze the risk of death if the PaO 2 was at least 300 mm Hg. We understand that the authors did fi nd excess mortality in their intended study group (and in those with a PaO 2 of greater than 200 mm Hg) even after adjust ment for illness severity. We are concerned that their negative conclusion is based on a diff erent (and smaller) post hoc subset of patients with a PaO 2 of greater than 400 mm Hg. By contrast, Kilgannon and colleagues [4] re-analyzed their data and reported a clear dose response with lowest hospital mortality in the PaO 2 range of 60 to 99 mm Hg and they reported a 24% increase in mortality risk for every 100 mm Hg increase in PaO 2 . We thank O'Driscoll and Howard for their letter. We share the view that pulse oximetry monitoring in cardiac arrest patients is desirable. However, we wish to emphasize that our methods simply sought to replicate those of Kilgannon and colleagues [2] given the characteristics of our national database. Th e view that the PaO 2 associated with the highest A-a gradient [1] is a poorer marker of the chance of exposure to hyperoxemia than the fi rst blood gas measurement [2] was not supported by our fi ndings. In a sample of 100 patients with detailed arterial blood gas information, the worst PaO 2 was signifi cantly more representative of mean PaO 2 than was the fi rst PaO 2 in the ICU (P <0.0001 for the fi rst 24, 48, or 72 hours), as reported in our paper. In terms of the speeding analogy, the slowest speed achieved by a driver tells us a lot more about his or her mean speed (the speed that may well matter the most) than does the highest speed in the fi rst 10 minutes. Moreover, our conclusions were not based on the lack of eff ect at a PaO 2 of greater than 400 mm Hg (a parameter chosen by Kil gannon and colleagues [2] ) but on a considered assess ment of all observations. We advise caution in over-inter preting data from a study in which no adjustment for illness severity was possible and more than 30% of data were missing [1] . Similarly, the study of de Jonge and colleagues [3] requires validation. We are currently conducting such an 
